关于我们
关于HLB
领导寄语
沿革
地位
集团
制药,生物科技
造船
事业
制药,生物科技
细胞毒性药物
靶向治疗药物
免疫疗法
特殊船舶
GRE PIPE事业
投资者关系
股价信息
公司公告
公关
IR LETTER
报刊
资料室
职业
招聘
中文
韩文
英文
Best-in-class
anticancer
drug
HLB研发的Rivocerenib追求Best-in-class
Rivoceranib为针对癌症优秀的靶向药物
Leader of Global
Pharma
HLB navigates the way to the future by developing
First-in-class drugs with continuous innovation and challenges.
IR Letter
About the Progress of the Global Ri...
∙ On February 26, HLB signed a binding term sheet with Adenchen Laboratories, the original developer of Rivoceranib, t...
Apealea completes Pre-NDA meeting
On April 30th, Oasmia pharmaceutical AB (Oasmia) held FDA's ovarian cancer pre-NDA meeting for Apealea, which Elevar Th...
Press Release
Elevar Therapeutics Announces Orpha...
Elevar Therapeutics, Inc. (“Elevar”), a fully integrated biopharmaceutical company built on the promise of elevating t...
Elevar Therapeutics announces Licen...
Elevar Therapeutics, Inc. (“Elevar”), a fully integrated biopharmaceutical company built on the promise of elevating tre...
Report
Low-dose apatinib monothe...
AbstractThe therapeutic regimen for small cell lung cancer (SCLC)...
Tumor Angiogenesis and An...
AbstractAngiogenesis is the process through which novel blood ves...